Concizumab

Drug Profile

Concizumab

Alternative Names: Anti-TFPI; mAb-2021; NN-7415; NNC-0172-0000-2021; NNC-0172-2021; NNC-172-2021

Latest Information Update: 13 Jun 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Novo Nordisk
  • Class Antihaemorrhagics; Blood coagulation factors; Monoclonal antibodies
  • Mechanism of Action Lipoprotein-associated coagulation inhibitor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Haemophilia

Most Recent Events

  • 08 Jun 2017 Phase-II clinical trials in Haemophilia (Prevention) in Sweden (SC) (EudraCT2016-000510-30)
  • 02 Jun 2017 Novo Nordisk plans a phase II trial for Haemophilia A (Prevention) in Thailand (TCTR20170512002)
  • 15 Dec 2016 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top